Skip to main content
. 2021 Mar 5;29(4):529–539.e3. doi: 10.1016/j.chom.2021.03.002

Figure 2.

Figure 2

Neutralization of variants by vaccine and convalescent sera

(A and B) Serum ID50 (A) and ID80 (B) titers of neutralization of each variant relative to D614G by vaccine sera (top 2 rows) and convalescent sera. Dashed thin lines represent individual samples; thick black lines represent geometric means of each sample group as indicated on the right. NT, not tested. Samples in dark and light red colors in the Moderna panel against B.1.1.7 are D29 and D57 samples, respectively. See also Table S1.

(C) Fold decline of ID50 (left) and ID80 (right) titers for each variant over D614G (D614G/variant) for each serum sample set as identified. Numbers on top of each plot show median fold differences. Upper and lower border of each box represent IQR of the fold differences, respectively, and the middle bars in boxes represent group median. Statistical significance of comparisons are indicated in all panels as p < 0.05 (p < 0.064 corresponds to q < 0.1), ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001. Wilcoxon signed-rank paired test for (A and B); Wilcoxon rank-sum test for (C). See also Table S2.